Santen has brought to market four innovative ophthalmic products covering a broad range of conditions, from allergy and infection, to glaucoma.
Vistakon Pharmaceuticals, LLC, through a partnership agreement, was granted the exclusive U.S. distribution rights to the Santen products IQUIX®, QUIXIN®, BETIMOL® and ALAMAST®.
Santen will continue to manufacture all of these products and maintain responsibility for clinical and regulatory activities.
or click on the logos of each product for more information
IQUIX® (levofloxacin ophthalmic solution) 1.5%
is the newest FDA approved fluoroquinolone
for the treatment of bacterial corneal ulcer.
Quixin® (levofloxacin ophthalmic solution) 0.5%–newer fluoroquinolone for the treatment of bacterial conjunctivitis.
Betimol® (timolol ophthalmic solution) 0.25% and 0.5%–for the treatment of elevated intraocular pressure.
Alamast® (pemirolast potassium ophthalmic solution) 0.1%–the first mast cell stabilizer indicated for the prevention of itching of the eye due to allergic conjunctivitis.
Visit Santen Worldwide for a Complete Product List
